Literature DB >> 2713492

Interaction of platelet factor four with cultured vascular endothelial cells.

M E Rybak1, M A Gimbrone, P F Davies, R I Handin.   

Abstract

Platelets secrete a low-molecular-weight protein, platelet factor four (PF-4), which binds to and neutralizes heparin and related sulfated glycosaminoglycans (GAGs). To examine the interactions of PF-4 with the GAGs present on endothelial cell surfaces, we incubated 125I-PF-4 with cell suspensions derived from confluent monolayers of cultured bovine aortic endothelium. Binding of 125I-PF-4 was inhibited by a 100-fold excess of nonradioactive PF-4 and varied with duration and temperature of incubation. At 4 degrees C, binding reached equilibrium at 20 minutes with kd = 2.87 mumol/L and Bmax of 63.83 pmol/10(5) cells. Binding capacity was reduced 83.4% by brief incubation of endothelial cells with trypsin and 46.67% by incubation with Flavobacterium heparinase, but was unchanged by chondroitin-ABCase treatment. At 37 degrees C, PF-4 was internalized by confluent monolayer of bovine aortic endothelial cells primarily through low-affinity adsorptive endocytosis. The internalized PF-4 was degraded to amino acids and small peptides with 50% conversion after 18-hour incubation. These studies demonstrate that a secreted platelet protein can bind to and enter endothelial cells. Binding may explain the rapid clearance of released PF-4 from plasma and could have important local effects on endothelial structure and function.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2713492

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Activation of human macrophages by allogeneic islets preparations: inhibition by AOP-RANTES and heparinoids.

Authors:  Séverine Sigrist; José Oberholzer; Alain Bohbot; Guy Esposito; Karim Mandes; Roger Lamartine; Christian Toso; Pascal Bucher; Michel Pinget; Laurence Kessler
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

2.  Platelet factor 4 modulates the mitogenic activity of basic fibroblast growth factor.

Authors:  J B Watson; S B Getzler; D F Mosher
Journal:  J Clin Invest       Date:  1994-07       Impact factor: 14.808

3.  Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells.

Authors:  G P Visentin; S E Ford; J P Scott; R H Aster
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

4.  Dose dependent effects of platelet derived chondroitinsulfate A on the binding of CCL5 to endothelial cells.

Authors:  Christian Weingart; Peter J Nelson; Bernhard K Krämer; Matthias Mack
Journal:  BMC Immunol       Date:  2008-12-10       Impact factor: 3.615

5.  Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia.

Authors:  M Margaret Prechel; Jeanine M Walenga
Journal:  Thromb J       Date:  2013-04-05

6.  The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation.

Authors:  A D Luster; S M Greenberg; P Leder
Journal:  J Exp Med       Date:  1995-07-01       Impact factor: 14.307

7.  Visualization of chemokine binding sites on human brain microvessels.

Authors:  A V Andjelkovic; D D Spencer; J S Pachter
Journal:  J Cell Biol       Date:  1999-04-19       Impact factor: 10.539

8.  gro-beta, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice.

Authors:  Y Cao; C Chen; J A Weatherbee; M Tsang; J Folkman
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.